Aethlon Medical Reports Q1 FY2027 Results, $4.9M Cash, and 12-Month Runway

summarizeSummary

Aethlon Medical reported Q1 FY2027 results with a narrower net loss, $4.9M in cash, and a post-quarter $4.0M raise, extending runway to at least 12 months. The Hemopurifier Phase 1 study advanced to its final cohort.

check_boxKey Events · Earnings and Guidance · AEMD

• Q1 FY2027 Net Loss Narrows

  Net loss was $1.55 million, down from $1.76 million in the prior-year quarter, driven by an 11.9% reduction in operating expenses to $1.6 million.

• Cash Runway Extended to 12 Months

  Cash and equivalents were $4.9 million as of June 30, 2026, and a post-quarter public offering raised approximately $4.0 million in gross proceeds. Management states cash is sufficient for at least the next 12 months.

• Hemopurifier Phase 1 Advances

  First participant was dosed in the third and final cohort of the Phase 1 oncology study in Australia. Early biomarker signals from initial cohorts support continued evaluation.

• Long COVID Publication Accepted

  A manuscript on extracellular vesicle characteristics in Long COVID patients was accepted for publication in the International Journal of Molecular Sciences.

auto_awesomeAnalysis · AEMD · Industrial Applications And Services

Aethlon Medical reported Q1 FY2027 results with a net loss of $1.55 million, down from $1.76 million a year earlier, and operating expenses down 11.9% to $1.6 million. Cash stood at $4.9 million as of June 30, 2026, and the company raised approximately $4.0 million in gross proceeds after quarter-end. Management states cash is sufficient for at least the next 12 months, addressing the going-concern risk flagged in the June 10-K. The Hemopurifier program advanced with the first participant dosed in the third and final cohort of the Phase 1 oncology study in Australia, and a Long COVID manuscript was accepted for publication. This is the first disclosure of quarterly results and updated runway guidance, making it a material update for investors.